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taken for perfusion preparation through to its ﬁnalization
was considerably longer with pamidronate: for every
patient treated with pamidronate on average 3.5 could 
be treated with zoledronic acid. Under normal clinical
practice (permanent patient vigilance and infusion times
according to labeling instructions), zoledronic acid
required 105 minutes less nursing time, valued at €26.25.
Given that also fewer supplies were used (costing €7.29),
the total cost difference reduced to an additional €32.43
with zoledronic acid. According to the clinical trials, 18.7
percentage points more patients had a complete response
with zoledronic acid than with pamidronate, and average
duration of complete response per treatment administered
was 4.1 days longer. Thus incremental costs amounted 
to €173.68 per additional complete response and €7.82
per additional day of complete response. These results are
dependent on clinical practice, particularly regarding the
savings in personnel costs, and could be higher or lower
in circumstances that are different to the most frequent
scenario considered here. CONCLUSION: Compared to
pamidronate, zoledronic acid considerably shortens treat-
ment time and has an acceptable incremental cost-efﬁcacy
ratio.
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OBJECTIVE: To estimate incremental costs of
Capecitabine versus 5-ﬂuorouracil/leukoverin (5FU/LV)
for Dutch colon-rectal cancer patients. Treatment with
capecitabine reﬂects a new chemotherapy for patients
with colorectal cancer. Oral capecitabine has a major
advantage over the current treatment with intravenous 
5-FU/LV (Mayo-protocol), as it may be used at home.
Furthermore, capecitabine seems to have a better safety
proﬁle than 5FU/LV. Capecitabine may be applied both
in the palliative and the adjuvant setting. METHODS: We
used cost analysis to estimate the pharmaco-economic
proﬁle of capecitabine. This pharmacoeconomic tech-
nique is justiﬁed as effectiveness may be assumed similar
for both treatments. Costs in the analysis relate to extra
drug costs of capecitabine over 5FU/LV. Beneﬁts of
capecitabine relate to reduced costs for outpatient hospi-
tal administration of 5FU/LV, for travel hence and forth
and for treatment of side effects of chemotherapy. Files
of 65 colorectal-cancer patients recently treated in the
Isala Clinics (Zwolle, Netherlands) were investigated to
assess numbers of outpatient visits for 5FU/LV adminis-
tration, health-care and medications for adverse-effects
and travel time. Risk reductions for adverse-effects of
5FU/LV were drawn from the literature. Costing was
done using prices listed in the Dutch guideline for 
pharmaco-economic research. RESULTS: At the current
market price, which is almost fourfold that of 5FU/LV 
per treatment, oral capecitabine is cost-saving compared
to intravenous 5FU/LV. Costs per treatment for
capecitabine were 15–25% below those for 5FU/LV, 
both in palliative and adjuvant settings. This result 
was robust in sensitivity analysis, with a 10% decrease in 
costs as the minimum. Cost reductions primarily relate 
to a decrease in hospital costs for administering 5FU/LV.
CONCLUSIONS: Treatment with oral capecitabine 
may be cost saving for Dutch colorectal patients. Fur-
thermore, increases in quality-of-life related to treatment
in the home rather than the hospital setting may be
expected.
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OBJECTIVES: Epoetin reduces the transfusion rate in
cancer patients undergoing chemotherapy, but it has 
a high cost and a variable response rate. The Anemia
Guidelines Development Group recommended to limit its
use when before-cycle haemoglobin is <10g/dL and the
expected drop is >1g/dL/cycle. With the present study we
aimed at assessing the propensity to use epoetin in realife
practice and its economic implications. METHODS:
A retrospective study enrolled 170 cancer patients in 3
Italian centres. Chart review allowed to estimate clinical
outcomes and consumption of health care resources
within the 3-month study period: the costs were calcu-
lated from the perspective of the National Health Care
System and transformed to logarithms before analysis. 
An Epoetin Administration Index (EAI) was calculated
through Classiﬁcation and Regression Trees (CRTs).
RESULTS: The population, aged 60.5 years (sd 10.2),
was equally distributed among three cancer sites: gas-
trointestinal, head-neck-lung and ovary. Epoetin was
administered to 70% of the patients, but only 5% of 
them had a pre-chemotherapy haemoglobin <10g/dL. We
thus calculated that epoetin was used inappropriately 
in 40% of the patients, while it was inappropriately 
not administered in 65% of the patients who got trans-
fusions, instead. The EAI was higher in patients enrolled
by center n°3, those with ovary cancer and with a higher
haemoglobin or a higher anemization speed. Accuracy 
of the propensity score was high (accuracy 93%). The
CRT splitted patients based on a haemoglobin cutoff of
9.9g/dL: more anemic patients had a 1 :7 odds to get
epoetin, despite the guidelines. Overall cancer care costs
€9,686 per epoetin-treated patient and €4,199 per trans-
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fusion-treated patient but the average epoetin-and-
transfusion-free costs were very similar in the two groups.
The costs varied highly between centres, but a high EAI
independently decreased the without-epoetin-costs by
15%. CONCLUSIONS: An appropriate and homoge-
neous use of epoetin might reduce the costs of cancer
treatment.
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The recent introduction on the French market of 
HerceptinTM, an innovative drug associated to a high
acquisition cost, justiﬁes its economic assessment.
OBJECTIVE: The study aim was to compare 8 chemo-
therapies as ﬁrst-line treatment in MBC (doxorubicin 
(D) + cyclophosphamide (C); 2 combinations of 5-
Fluorouracile (F), Epirubicin (E) and C i.e. FEC50 and
FEC100; D + paclitaxel (P); D + docetaxel (T); E + P; 
E + T; H + P. METHODS: The study methodology,
according to a French payer perspective, is a cost-
effectiveness analysis based on a decision tree model.
Assessment considers the period from the diagnosis of
metastasis until the end therapy or death. The clinical
data are obtained from recently published phase III ran-
domised trials. Effectiveness was assessed through time to
progression criteria. Chemotherapy procedures, incidence
of adverse events, patient transport and nurse care follow
up were collected. Hospital costs were estimated through
the National Costs References per DRG. Medication
costs were estimated from standard dosages. General
Nomenclature of Practitioner Acts (NGAP) was used to
valuate ambulatory follow-up care. A sensibility analysis
was led on efﬁcacy criteria and main drivers cost.
RESULTS: The mean cost by week without progression
is €550 for H + P, €424 for E + T, €417 for E + P, €418
for D + T, €438 for D + P, €374 for FEC50, €324 for
FEC100 and €365 for D + C. The most effective combi-
nation appears to be E + T, as and the ﬁnancial sacriﬁce
associated with an additional one week without progres-
sion, as compared to FEC100 for instance, is €895.
Anthracyclins (D or E) + taxans (P or T) combinations
show a complete dominance when compared to the H +
T strategy, but the latter is only offered to the subpopu-
lation of patients showing the receptor over-expression, a
potential negative predictor for response to chemo-
therapy. CONCLUSIONS: Although this type of analysis
favours the use of anthracyclins + taxans combinations in
ﬁrst-line treatment of MBC, our hypothesis has to be con-
ﬁrmed by clinical pharmaco-economical trials.
PCN13
GEMZAR RETROSPECTIVE ECONOMIC
ANALYSIS OF CLINICAL TRIALS (GREAT) IN
THE TREATMENT OF NON-SMALL-CELL LUNG
CANCER:A MULTI-COUNTRY COST-
MINIMISATION ANALYSIS
Aristides M1, Lees M2,Tilden DP1, Kielhorn A3, Stynes G1
1M-TAG Limited, London, United Kingdom; 2M-TAG Pty Ltd,
Chatswood West, NSW, Australia; 3Eli Lilly, Windlesham,
Surrey, United Kingdom
OBJECTIVES: Gemcitabine/cisplatin (GC) is one of
many novel chemotherapy regimens available for the
treatment of non-small cell lung cancer. This study con-
ducted two clinical trial-based economic evaluations 
comparing GC with other novel agent regimens in ﬁve
European countries: France, Germany, Italy, Spain, and
the UK. METHODS: The economic evaluations were
conducted using evidence from two randomised, con-
trolled trials of GC and the other novel regimens. The ﬁrst
analysis was based upon the trial published by Comella
et al. (2000) and compared GC with vinorelbine/cisplatin
(VC). The second analysis was based upon the trial pub-
lished by Schiller et al. (2000) and compared GC with
paclitaxel/cisplatin (PCI), paclitaxel/carboplatin (PCA)
and docetaxel/cisplatin (DC). In these trials, pivotal
health outcomes including overall and progression-free
survival were similar between GC and the other regimens
meaning cost-minimisation analysis was employed.
RESULTS: The analysis based on Comella et al. (2000)
found that GC was associated with lower total treatment
costs than VC in all ﬁve countries. The overall cost
savings associated with GC ranged from €802 in Spain to
£1,262 in the UK. The second analysis found that GC had
lower total treatment costs than both of the paclitaxel
regimens in all ﬁve countries. The overall cost savings 
for GC were greatest when compared against PCA and
ranged from €2,153 in Italy to €4,846 in France. GC was
associated with a small incremental cost compared to DC
in Germany (€95 per patient) and was cost saving in the
other four countries. CONCLUSIONS: GC was associ-
ated with lower total treatment costs than VC, PCI and
PCA from the perspective of the national health services
of ﬁve European countries. Given similar efﬁcacy ﬁndings
in these studies, a claim for cost-effectiveness of GC in
the treatment of advanced NSCLC is supported.
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OBJECTIVE: A number of new agents have become
available in the past decade for the treatment of non-
